title: [The influence of piracetam on behavior and brain receptors in C57BL/6 and BALB/c mice: nootropic and anxiolytic effects].
abstract: The influence of acute and long-term piracetam administration on the dynamics of rapid (non-specific, anxiolytic) and slow (specific, nootropic) behavioral drug effects, as well as on their interrelation with NMDA- and BDZ-receptors was studied in inbred mice strains differing in cognitive and emotional status--C57BL/6 and BALB/c. The BALB/c strain contained 17% less [3H]-flunitrazepam binding sites in frontal cortex and 22% less [3H]-MK801 binding sites in hippocampus as compared to those in C57BL/6 mice. Based on these data, BALB/c strain was used as a model of psychopathology, combining increased anxiety and cognitive deficit. Under the action of single, 7-fold, and 14-fold piracetam i.p. injections (200 mg/kg body weight, daily), a fast increase in NMDA-receptor density and slow escalation of the specific nootropic effect was observed in BALB/c mice. Non-specific anxiolytic effects in these mice increased for the first 1 - 7 days without any changes in BDZ-binding and then decreased to initial values accompanied by decrement of brain receptor concentration. Thus, in BALB/c mice, a slowly manifested specific nootropic action of piracetam develops, following an increase in NMDA receptor density, whereas the non-specific anxiolytic effect precedes the fast-paced changes in BDZ-binding site density.
authors.forename: G I
authors.initials: GI
authors.lastname: Kovalev
authors.forename: E A
authors.initials: EA
authors.lastname: Kondrakhin
authors.forename: R M
authors.initials: RM
authors.lastname: Salimov
authors.forename: G G
authors.initials: GG
authors.lastname: Neznamov
mesh_terms: D000818:Animals; D001007:Anxiety / Q000517:prevention & control* / Q000523:psychology; D001522:Behavior, Animal / Q000187:drug effects; D001665:Binding Sites; D003071:Cognition / Q000187:drug effects*; D004334:Drug Administration Schedule; D005625:Frontal Lobe / Q000187:drug effects / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018696:Neuroprotective Agents / Q000494:pharmacology*; D018697:Nootropic Agents / Q000494:pharmacology*; D010889:Piracetam / Q000494:pharmacology*; D011485:Protein Binding; D011963:Receptors, GABA-A / Q000235:genetics / Q000378:metabolism*; D016194:Receptors, N-Methyl-D-Aspartate / Q000819:agonists / Q000235:genetics / Q000378:metabolism*; D013045:Species Specificity
chemical_list: D018696:Neuroprotective Agents; D018697:Nootropic Agents; D011963:Receptors, GABA-A; D016194:Receptors, N-Methyl-D-Aspartate; D010889:Piracetam